NINDS/HHS Supply Service Center

National Institute Of Neurological Disorders And Stroke

Investigators

Abstract

The National Institute of Neurological Disorders and Stroke (NINDS) is supporting a randomized, multicenter phase III clinical trial comparing combination therapy with interferon β[unreadable] la (Avonex) and glatiramer acetate (Copaxone) to either agent alone in the treatment of the relapsing-remitting (RR) form of multiple sclerosis (MS).